Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTM-004
- Development stage
- Preclinical
- Lead developer
- Neumentum
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
NTM-004 is a non-opioid, small molecule new chemical entity (NCE) being developed by Neumentum for the treatment of acute and chronic pain, as well as inflammation. It is an intravenous (IV) analogue of acetaminophen (APAP) designed to provide potent analgesic efficacy without the hepatotoxicity associated with traditional acetaminophen. Currently in the IND-enabling stage, NTM-004 aims to provide a safer alternative to both opioids and high-dose acetaminophen for pain management in clinical settings. The compound is part of a broader pipeline focused on addressing the opioid crisis by providing effective non-opioid alternatives for pain management.
Beyond the preview
Go deeper on NTM-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTM-004.